Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Thalmann

Showing results (231-240 of 307) with videos related to

Pageof 31
Sort By:
International Journal of Cancer|May 4, 2004
Cellular interactions in the tropism of prostate cancer to boneRobert A Sikes, Brian E Nicholson, Kenneth S Koeneman, et al.
The Prostate|January 15, 2015
Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out immunocompromised miceChristian Wetterauer, Tatjana Vlajnic, Julia Schüler, et al.
BJU International|October 18, 2013
Outcomes of radical cystectomy with extended lymphadenectomy alone in patients with lymph node-positive bladder cancer who are unfit for or who decline adjuvant chemotherapyPascal Zehnder, Urs E Studer, Siamak Daneshmand, et al.
Science Translational Medicine|June 8, 2012
Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancerClaire Biot, Cyrill A Rentsch, Joel R Gsponer, et al.
Frontiers in Oncology|February 22, 2021
Corrigendum: Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor HeterogeneityFederico La Manna, Marta De Menna, Nikhil Patel, et al.
Frontiers in Oncology|July 14, 2020
Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor HeterogeneityFederico La Manna, Marta De Menna, Nikhil Patel, et al.
Plos One|February 23, 2012
iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancerIshtiaq Rehman, Caroline A Evans, Adam Glen, et al.
BJU International|April 28, 2026
'BJUI Clinical Dilemma': Recurrent high-grade non-muscle-invasive bladder cancer in 2026Vignesh T Packiam, Peter C Black, James W F Catto, et al.
Cell Death & Disease|October 24, 2014
Nuclear iASPP may facilitate prostate cancer progressionE V Morris, L Cerundolo, M Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2013
Characterization and clinical relevance of ALDHbright populations in prostate cancerClémentine Le Magnen, Lukas Bubendorf, Cyrill A Rentsch, et al.
Pageof 31

Showing results (231-240 of 307) with videos related to

Sort By:
Pageof 31
International Journal of Cancer|May 4, 2004
Cellular interactions in the tropism of prostate cancer to boneRobert A Sikes, Brian E Nicholson, Kenneth S Koeneman, et al.
The Prostate|January 15, 2015
Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out immunocompromised miceChristian Wetterauer, Tatjana Vlajnic, Julia Schüler, et al.
BJU International|October 18, 2013
Outcomes of radical cystectomy with extended lymphadenectomy alone in patients with lymph node-positive bladder cancer who are unfit for or who decline adjuvant chemotherapyPascal Zehnder, Urs E Studer, Siamak Daneshmand, et al.
Science Translational Medicine|June 8, 2012
Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancerClaire Biot, Cyrill A Rentsch, Joel R Gsponer, et al.
Frontiers in Oncology|February 22, 2021
Corrigendum: Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor HeterogeneityFederico La Manna, Marta De Menna, Nikhil Patel, et al.
Frontiers in Oncology|July 14, 2020
Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor HeterogeneityFederico La Manna, Marta De Menna, Nikhil Patel, et al.
Plos One|February 23, 2012
iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancerIshtiaq Rehman, Caroline A Evans, Adam Glen, et al.
BJU International|April 28, 2026
'BJUI Clinical Dilemma': Recurrent high-grade non-muscle-invasive bladder cancer in 2026Vignesh T Packiam, Peter C Black, James W F Catto, et al.
Cell Death & Disease|October 24, 2014
Nuclear iASPP may facilitate prostate cancer progressionE V Morris, L Cerundolo, M Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2013
Characterization and clinical relevance of ALDHbright populations in prostate cancerClémentine Le Magnen, Lukas Bubendorf, Cyrill A Rentsch, et al.
Pageof 31